[go: up one dir, main page]

MX2015011775A - Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. - Google Patents

Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.

Info

Publication number
MX2015011775A
MX2015011775A MX2015011775A MX2015011775A MX2015011775A MX 2015011775 A MX2015011775 A MX 2015011775A MX 2015011775 A MX2015011775 A MX 2015011775A MX 2015011775 A MX2015011775 A MX 2015011775A MX 2015011775 A MX2015011775 A MX 2015011775A
Authority
MX
Mexico
Prior art keywords
formulations
methods
levocetirizine
montelukast
anafilaxis
Prior art date
Application number
MX2015011775A
Other languages
English (en)
Other versions
MX377510B (es
Inventor
Bruce Chandler May
Original Assignee
Inflammatory Response Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflammatory Response Res Inc filed Critical Inflammatory Response Res Inc
Publication of MX2015011775A publication Critical patent/MX2015011775A/es
Publication of MX377510B publication Critical patent/MX377510B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las modalidades descritas aquí incluyen métodos y formulaciones para tratar la anafilaxis y reacciones alérgicas agudas relacionadas. Los métodos y formulaciones incluyen, pero no se limitan a, métodos y formulaciones para proporcionar concentraciones efectivas de levocetirizina y montelukast al paciente que lo necesite. Los métodos y formulaciones pueden comprender elementos de liberación convencionales y/o modificados, proporcionados para proporcionar el fármaco al paciente.
MX2015011775A 2013-03-13 2014-03-07 Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. MX377510B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780452P 2013-03-13 2013-03-13
PCT/US2014/021705 WO2014164281A1 (en) 2013-03-13 2014-03-07 Use of levocetirizine and montelukast in the treatment of anaphylaxis

Publications (2)

Publication Number Publication Date
MX2015011775A true MX2015011775A (es) 2015-12-01
MX377510B MX377510B (es) 2025-03-10

Family

ID=51658845

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011775A MX377510B (es) 2013-03-13 2014-03-07 Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.

Country Status (11)

Country Link
US (3) US20150352102A1 (es)
EP (1) EP2969001B1 (es)
JP (1) JP6313413B2 (es)
KR (1) KR20150138848A (es)
CN (1) CN105163806A (es)
AU (1) AU2014249530B2 (es)
CA (1) CA2901411A1 (es)
ES (1) ES2709849T3 (es)
MX (1) MX377510B (es)
RU (1) RU2705097C2 (es)
WO (1) WO2014164281A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802853C (en) 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
CA2901413A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of vasculitis
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
CN105517631A (zh) 2013-03-13 2016-04-20 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US12514855B2 (en) 2020-05-19 2026-01-06 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
RU2757845C1 (ru) * 2020-07-13 2021-10-21 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ профилактики бронхиальной астмы у детей с рецидивирующим ларинготрахеитом и сопутствующими аллергическими заболеваниями

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207292B2 (en) * 2007-02-12 2012-06-26 Michalis Nicolaou Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
EP2415227A1 (en) * 2009-04-01 2012-02-08 Nokia Siemens Networks OY Optimized interface between two network elements operating under an authentication, authorization and accounting protocol
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CA2802853C (en) * 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US20130030009A1 (en) * 2010-12-30 2013-01-31 Ziv Harish Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen
JP5996553B2 (ja) * 2010-12-30 2016-09-21 ジブ エム．ディー． ハリシュ， 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제

Also Published As

Publication number Publication date
CN105163806A (zh) 2015-12-16
EP2969001B1 (en) 2018-12-19
KR20150138848A (ko) 2015-12-10
JP6313413B2 (ja) 2018-04-18
US20170368059A1 (en) 2017-12-28
MX377510B (es) 2025-03-10
AU2014249530B2 (en) 2018-08-30
AU2014249530A1 (en) 2015-08-27
EP2969001A1 (en) 2016-01-20
JP2016512261A (ja) 2016-04-25
US20200101067A1 (en) 2020-04-02
US20150352102A1 (en) 2015-12-10
RU2705097C2 (ru) 2019-11-05
RU2015134418A3 (es) 2018-03-20
RU2015134418A (ru) 2017-04-18
WO2014164281A1 (en) 2014-10-09
ES2709849T3 (es) 2019-04-17
EP2969001A4 (en) 2016-09-07
CA2901411A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
MX2015003140A (es) Formulaciones de enzalutamida.
MX379228B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
ECSP15026557A (es) Compuestos y sus métodos de empleo
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
GT201400288A (es) "compuestos de fenoxietil piperidina"
UY35747A (es) Derivados sustituidos de fenilalanina
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.

Legal Events

Date Code Title Description
FG Grant or registration